Antiviral drugs

New England Journal of Medicine

Volumn 340, Issue 16, 1999, Pages 1255-1265

  Balfour Jr , Henry H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMANTADINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; LAMIVUDINE; PENCICLOVIR; RIBAVIRIN; RIMANTADINE; VALACICLOVIR;

ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CHICKENPOX; CYTOMEGALOVIRUS; DRUG APPROVAL; DRUG BIOAVAILABILITY; GASTROINTESTINAL DISEASE; HEADACHE; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KIDNEY DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; VIRUS INHIBITION; VIRUS RESISTANCE;

ANTIMETABOLITES; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MICROBIAL; HEPATITIS; HERPESVIRIDAE INFECTIONS; HUMANS; MOLECULAR STRUCTURE; RESPIRATORY TRACT INFECTIONS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS DISEASES;

EID: 0344938363     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199904223401608     Document Type: Review

References (100)

1. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 1977;74:5716-20.
2. Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978;253:8721-7.
3. Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother 1980;18:443-7.
4. Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985;82:2473-7.
5. Dense D, Cheng Y-C, Furman PA, St Clair MH, Elion GB. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate: effects on primer-template function. J Biol Chem 1981;256:11447-51.
6. Furman PA, St Clair MH, Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 1984;259:9575-9.
7. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983;12:Suppl B: 29-37.
8. Balfour HH Jr. Acyclovir. In: Peterson PK, Verhoef J, eds. The antimicrobial agents annual. Vol. 3. New York: Elsevier Science, 1988:345-60.
9. Cole NL, Balfour HH Jr. Varicella-zoster virus does not become more resistant to acyclovir during therapy. J Infect Dis 1986;153:605-8.
10. Fletcher CV, Englund JA, Edelman CK, Gross CR, Dunn DL, Balfour HH Jr. The pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991;35:938-43.
11. Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982;73:Suppl 1A:229-35.
12. Corey L, Fife KH, Benedetti JK, et al. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 1983;98:914-21.
13. Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308:1448-53.
14. Dunkle LM, Arvin AM, Whitley RJ, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-44.
15. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7.
16. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39.-2759-64.
17. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double-blind clinical trial. Genitourin Med 1997;73:110-6.
18. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39: 1546-53.
19. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998;177: 48-56.
20. Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721-9.
21. Hamzeh FM, Lietman FS. Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir. Antimicrob Agents Chemother 1991;35:1818-23.
22. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-4. [Errata, Nature 1992;359:85, 1993;366:756.]
23. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-2.
24. Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ, Balfour HH Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987;257:3082-7.
25. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydraxy-2-propoxymethyl)-guanine. J Infect Dis 1985;152:833-4.
26. Winston DJ, Wirin D, Snaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.
27. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomogalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-7.
28. Gane E, Saliba F, Valdecasas GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-33. [Erratum, Lancet 1998;351:454.]
29. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus-and cytomegalovirus-seropositive patients. Clin Ther 1995; 17:425-32.
30. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-57.
31. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987;31:1238-42.
32. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpes-virus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989;33:1765-73.
33. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellers J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996;276:44-9.
34. Tyring S, Barbarash RA, Nahlik JE, et at Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:89-96.
35. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 1989;40:213-85.
36. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with cither foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20. [Erratum, N Engl J Med 1992;326:1172].
37. Safrin S, Crumpacker C, Chads P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutanoeus herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325:551-5.
38. Wray SK, Gilbert BE, Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res 1985;5:39-48.
39. Wray SK, Gilbert BE, Noall MW, Knight V. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 1985;5:29-37.
40. Paroni R, Del Puppo M, Borghi C, Sirtori CR, Galli Kienle M. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Im J Clin Pharmacol Ther 1989;27:302-7.
41. Connor JD. Ribavirin pharmacokinetics. Pediatr Infect Dis J 1990;9: Suppl:S91-S92.
42. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
43. Hugghis JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164: 1119-27.
44. Reichard O, Norkrans G, Frydén A, Braconier J-H, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:83-7.
45. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992;3:21-30.
46. Aoki FY, Sitar DS, Amantadine kinetics in healthy elderly men. implications for influenza prevention. Clin Pharmacol Ther 1985;37:137-44.
47. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am 1987;1:459-78.
48. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother 1995;29:299-310.
49. Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 1969;281:579-84.
50. Dolin R., Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982;307:580-4.
51. Dorr RT. Interferon-α in malignant and viral diseases: a review. Drugs 1993;45:177-211.
52. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986;315:1059-64.
53. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A Interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-6.
54. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
55. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
56. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
57. McKenzie R, Fried MW, Sallic R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
58. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997;76:369-80.
59. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R, Valaciclovir International Herpes Simplex Virus Study Group. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481-6.
60. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984;251:2103-7.
61. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997;99:1092-7.
62. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized, double-blind, controlled trial in bone-marrow-transplant recipients. N Engl J Med 1981;305:63-7.
63. Lazarus H, Belanger R, Candoni A, et al. Efficacy and safety of penciclovir (PCV) for the treatment of HSV infections in immunocompromised (IC) patients. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997:226. abstract.
64. Spruance SL, Rea TL, Thoming C, Tucker R., Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. JAMA 1997;277: 1374-9.
65. Spruance SL, Stewart JCB, Rowe NH, McKcough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-90.
66. Spruance SL, Hamill ML, Hoge WS, Davis LG, Mills J. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA 1988;260: 1597-9.
67. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med 1991; 324:450-4.
68. Kimberlin D, Powell D, Gruber W, et al. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996;15:247-54.
69. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996;87:69-73.
70. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986;314:144-9.
71. Balfour HH Jr, Kelly JM, Suarez CS, et al. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990;116:633-9.
72. Balfour HH Jr, Rotbart HA, Feldman S, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. J Pediatr 1992;120:627-33.
73. Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children - a collaborative study. J Pediatr 1982;101: 622-5.
74. Balfour HH Jr. Intravenous acyclovir therapy for varicella in immunocompromised children. J Pediatr 1984;104:134-6.
75. Carcao MD, Lau RC, Gupta A, Huerter H, Koren G, King SM. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatr Infect Dis J 1998;17:626-31.
76. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med 1996;335:32-42.
77. Huff JC. Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988;85:Suppl 2A:84-9.
78. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986;93:763-70.
79. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acydovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900.
80. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acydovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:376-83.
81. Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981;245:1128-31.
82. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection: a randomized double-blind study. N Engl J Med 1983;308:1443-7
83. Levy BT, Graber MA. Respiratory syncytial virus infection in infants and young children. J Fam Pract 1997;45:473-81.
84. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dyspiasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
85. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997;102:Suppl 3A:55-60.
86. England JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med 1997;102:Suppl 3A:61-70.
87. Hoofnagie JH, Di Bisceglie AM. The treatment of chronic viral hep atitis. N Engl J Med 1997;336:347-56.
88. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
89. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
90. Deray G, Martinez F, Kadama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989;9:316-21.
91. Cope AV, Sabin C, Burroughs A, Rolies K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997;176:1484-90.
92. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749-53.
93. Lowance D, Neumayer H-H, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med (in press).
94. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702.
95. Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991;115:19-21.
96. Erice A, Gil-Roda C, Perez J-L, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997;175: 1087-92.
97. von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23.
98. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997;337:874-80.
99. Holwerda BC. Herpesvirus proteases: targets for novel antiviral drugs. Antiviral Res 1997;35:1-21.
100. Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:105-14. [Erratum, N Engl J Med 1997;337:1019.]